Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Hepatitis C Disease Forecast and Market Analysis to 2035 - Forecasts, Treatment, Marketed Drugs, Pricing, Reimbursement, and Access & Pipeline - ResearchAndMarkets.com

Research and Markets
Posted on: 15 Feb 18

The "Hepatitis C Disease Forecast and Market Analysis to 2035" report has been added to ResearchAndMarkets.com's offering.

Hepatitis C is a blood-borne liver disease caused by the hepatitis C virus (HCV). HCV belongs to the Flaviviridaevirus family, and is a communicable disease spread primarily through direct contact with the blood or the bodily fluids of an infected individual, including sexual and mother-to-child transmission. Hepatitis C infection normally does not produce signs or symptoms and, as such, most people who are infected do not know they have the disease.

Market Snapshot

  • Falling disease prevalence and anticipated price decreases as competition intensifies will drive a net decline in market value.
  • Harvoni remains the dominant option for GT-1/4 patients, but has ceded share to cheaper rivals as competition intensifies.
  • Cases are expected to decline, driven by complexities in high-risk populations, demographics, and treatment developments.
  • Mavyret's approval at a substantial discount to Epclusa paves the way for a further decline in Gilead's HCV revenues.
  • Lack of unmet need and declining market value prompts Johnson & Johnson and Merck & Co to discontinue pipeline regimens.
  • Pricing is the key differentiator for drugs in this market.

Key Topics Covered:

Forecast: Hepatitis C

  • Executive Summary
  • Market Dynamics
  • Forecast and Future Trends
  • Market Definition and Methodology
  • Primary Research Methodology
  • Bibliography
  • Product Profile: Daklinza
  • Product Profile: Epclusa
  • Product Profile: Harvoni
  • Product Profile: Mavyret
  • Product Profile: Sovaldi
  • Product Profile: Viekira Pak Franchise
  • Product Profile: Vosevi
  • Product Profile: Ximency
  • Product Profile: Zepatier

Treatment: Hepatitis C

  • Executive Summary
  • Primary Research Methodology
  • Disease Definition And Diagnosis
  • Patient Segmentation
  • Current Treatment Options
  • Prescribing Trends
  • Unmet Needs In Hepatitis C

Epidemiology: Hepatitis C in the US, Japan, and 5EU

  • Executive Summary
  • Disease Overview
  • Sources And Methodology
  • Forecast
  • Epidemiologist Insight
  • Strengths And Limitations
  • Bibliography

Marketed Drugs: Hepatitis C

  • Executive Summary
  • Product Overview
  • Product Profile: Daklinza
  • Product Profile: Epclusa
  • Product Profile: Harvoni
  • Product Profile: Mavyret
  • Product Profile: Sovaldi
  • Product Profile: Viekira Pak Franchise
  • Product Profile: Vosevi
  • Product Profile: Ximency
  • Product Profile: Zepatier

Hepatitis C Pricing, Reimbursement, and Access

  • Executive Summary
  • Regulatory Labels
  • Payer Archetypes
  • Access to Recently Launched and Pipeline Products
  • Evidentiary Requirements and Future Pipeline Potential
  • US Pricing
  • US Reimbursement
  • Japan
  • Pricing in the Five Major EU Markets
  • France
  • Germany
  • Italy
  • Spain
  • UK
  • Methodology

Pipeline: Hepatitis C

  • Executive Summary
  • Pipeline Trends

For more information about this report visit https://www.researchandmarkets.com/research/c6sgc2/hepatitis_c?w=4.

View source version on businesswire.com: http://www.businesswire.com/news/home/20180215005712/en/

Business Wire
www.businesswire.com

Last updated on: 15/02/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.